Sandoz, a division of Novartis, will invest €150 million to expand its antibiotic production in Europe over the next 3-5 years. At a plant in Austria, the company will introduce new technology for the production of oral amoxicillin for its flagship penicillin drug. The site in Spain will expand production of sterile penicillin active pharmaceutical ingredients and sterile API mixtures.